This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Limas, C. J. Search for Related Content PubMed PubMed Citation Articles by Limas, C. J.

(Circulation. 1997;95:1979-1980.)
© 1997 American Heart Association, Inc.

Articles

Cardiac Autoantibodies in Dilated Cardiomyopathy

A Pathogenetic Role?

Constantinos J. Limas, MD

From the Onassis Cardiac Surgery Center, Athens, Greece.

Correspondence to Constantinos J. Limas, MD, Department of Cardiology, Onassis Cardiac Surgery Center, 356 Syngrou Ave, 176 74 Athens, Greece.

	Introduction

 
Disturbances in both humoral and cellular immunity have been described in patients with dilated cardiomyopathy and have been implicated in the initiation and progression of this disease entity. In particular, a variety of autoantibodies against cardiac cellular proteins have been identified in dilated cardiomyopathy,^{1 2 3 4 5 6 7} and the list includes G-protein–linked receptors (such as the ß₁-adrenergic and muscarinic cholinergic receptors), myosin, mitochondrial proteins (such as the adenine nucleotide translocator and keto--acid dehydrogenase), actin, tubulin, heat shock proteins, and the sarcoplasmic reticulum ATPase. The list is likely to expand as more putative autoantigens are tested. The pathophysiological relevance of these autoantibodies, however, is far from clear. After all, low titers of autoantibodies are found in normal subjects and are part of the immunologic repertoire. Interpretation of the findings is further complicated by the fact that dilated cardiomyopathy is most likely nosologically heterogeneous, and immune mechanisms may be important in only a subset of patients with this disease. Furthermore, observations are routinely made in patients with established disease, and inferences about the mechanisms by which myocardial injury was initiated must, by necessity, be based on indirect and circumstantial evidence. These reservations notwithstanding, three possible mechanisms through which autoantibodies can participate in the pathophysiology of dilated cardiomyopathy may be distinguished.

1. Initiation of cardiac injury. Evidence that autoantibodies can directly damage the myocardium and initiate the sequence of events that lead to dilated cardiomyopathy comes exclusively from experimental models. For example, in genetically susceptible strains of mice, injection of anti-myosin antibodies leads to . . . [Full Text of this Article]

This article has been cited by other articles:

				A. S. Tutor, P. Penela, and F. Mayor Jr. Anti-{beta}1-adrenergic receptor autoantibodies are potent stimulators of the ERK1/2 pathway in cardiac cells Cardiovasc Res, October 1, 2007; 76(1): 51 - 60. [Abstract] [Full Text] [PDF]

				D. Jane-wit, C. Z. Altuntas, J. M. Johnson, S. Yong, P. J. Wickley, P. Clark, Q. Wang, Z. B. Popovic, M. S. Penn, D. S. Damron, et al. {beta}1-Adrenergic Receptor Autoantibodies Mediate Dilated Cardiomyopathy by Agonistically Inducing Cardiomyocyte Apoptosis Circulation, July 24, 2007; 116(4): 399 - 410. [Abstract] [Full Text] [PDF]

				D. Jane-wit, M. Yu, A. E. Edling, S. Kataoka, J. M. Johnson, L. B. Stull, C. S. Moravec, and V. K. Tuohy A Novel Class II-Binding Motif Selects Peptides That Mediate Organ-Specific Autoimmune Disease in SWXJ, SJL/J, and SWR/J Mice J. Immunol., December 1, 2002; 169(11): 6507 - 6514. [Abstract] [Full Text] [PDF]

				J. Muller, G. Wallukat, M. Dandel, H. Bieda, K. Brandes, S. Spiegelsberger, E. Nissen, R. Kunze, and R. Hetzer Immunoglobulin Adsorption in Patients With Idiopathic Dilated Cardiomyopathy Circulation, February 1, 2000; 101(4): 385 - 391. [Abstract] [Full Text] [PDF]

				L. Mestroni, C. Rocco, D. Gregori, G. Sinagra, A. Di Lenarda, S. Miocic, M. Vatta, B. Pinamonti, F. Muntoni, A. L. P. Caforio, et al. Familial dilated cardiomyopathy: Evidence for genetic and phenotypic heterogeneity J. Am. Coll. Cardiol., July 1, 1999; 34(1): 181 - 190. [Abstract] [Full Text] [PDF]

				E. A Woodcock, S. J Matkovich, and O. Binah Ins(1,4,5)P3 and cardiac dysfunction Cardiovasc Res, November 1, 1998; 40(2): 251 - 256. [Full Text] [PDF]